Diroximel fumarate for brain bleed swelling
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests a medicine called diroximel fumarate to reduce swelling around a bleeding stroke (intracerebral hemorrhage). If you or your loved one have had a brain bleed within the last 48 hours and are not too severely affected, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- The brain bleed must be within the first 48 hours and not require immediate surgery.
- You cannot be taking a similar medication (dimethyl fumarate) for another condition.
- You must not have a severe swallowing problem that requires a feeding tube.
- You must be able to give informed consent and have French health insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called cerebrolysin can help people who have a bleeding stroke in the outer part of the brain (lobar hemorrhage). It looks at safety and how well it works.
This trial tests if a drug called diroximel fumarate can help increase a natural antioxidant (glutathione) in the brain for people with schizophrenia. It aims to see if lowering inflammation and boosting brain protection might improve symptoms.
This trial tests whether a drug called Recombinant Factor VIIa (rFVIIa) can safely help stop bleeding in the brain during a hemorrhagic stroke. The goal is to give the drug as quickly as possible, within 2 hours of stroke onset, to see if it improves outcomes.
This trial compares two medicines (deferoxamine and colchicine) to see if they can prevent further brain damage after a spontaneous brain bleed (intracerebral hemorrhage). The goal is to improve recovery by reducing inflammation and iron-related damage.
This trial tests whether a medication called butylphthalide can help reduce brain swelling that sometimes occurs after emergency endovascular treatment (a minimally invasive procedure to restore blood flow) for certain types of stroke.
This trial studies deferoxamine, a medicine that targets iron-related injury, in people with an aneurysmal subarachnoid hemorrhage (a brain bleed caused by a burst aneurysm). It aims to improve neurologic recovery after the aneurysm is treated.
Hear when a new Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.